Fermenta Biotech Q1 FY27: consolidated PAT down 56% YoY as margins nearly halve

On a consolidated basis — the primary basis — Fermenta Biotech's Q1 FY27 (quarter ended June 30, 2026) revenue fell 10.6% YoY to ₹121.82 Cr (₹136.26 Cr a year ago) while it was roughly flat QoQ (+0.2% versus ₹121.58 Cr in Q4 FY26). Consolidated PAT fell far more sharply, down 55.9% YoY to ₹9.53 Cr from ₹21.60 Cr, and down 48.8% QoQ from ₹18.60 Cr, taking net margin to 7.55% from 14.89% YoY and 14.69% QoQ — margin has roughly halved. Standalone (parent-only) numbers tell a much milder story: revenue down just 6.0% YoY to ₹111.84 Cr and PAT down only 7.7% YoY to ₹14.99 Cr, a divergence well above 3 points versus the consolidated YoY decline. Per the auditors' consolidated review report, three subsidiaries posted a combined net loss after tax of ₹3.98 Cr for the quarter, which is the primary driver pulling group profit well below the standalone print — readers seeing the standalone number elsewhere should not read it as a contradiction.

Part of the QoQ profit drop is optical rather than a fresh sequential decline. Q4 FY26's consolidated PAT of ₹18.60 Cr included a one-time ₹9.07 Cr exceptional gain (reversal of a previously recognised provision against trade receivables); stripping that out, Q4's normalized PAT was ~₹9.53 Cr — almost identical to this quarter's ₹9.53 Cr print, so the real deterioration shows up YoY, not sequentially. Working the other way, this quarter's own profit was itself aided by a ₹2.05 Cr reversal of an inventory provision (created earlier against animal-feed semi-finished goods) embedded in cost of materials — a benefit that was nil in the year-ago quarter and ₹3.17 Cr in Q4 FY26. Excluding this item, the adjusted consolidated PAT YoY decline widens to roughly -65% versus the reported -55.9%. Neither the current nor year-ago quarter carried other exceptional items, so the underlying YoY comparison is otherwise clean.

The stock went into the print at ₹455, up 2.5% over the past month of trading.

We found no street/analyst estimates on record for this print, and a targeted search turned up no brokerage previews or consensus PAT figures for Fermenta Biotech's Q1 FY27, so vsStreet is unknown. There is also no prior management guidance on file and none was found via search, so the result cannot be graded against a stated outlook — management gives no formal guidance on record. On corporate developments, the most relevant item is FSSAI approval for a plant-source Vitamin D3 product (July 6, 2026), tied directly to the company's core bulk-drugs/Vitamin D3 franchise though with no revenue impact visible this quarter, alongside the stock's NSE listing effective August 4, 2026 — a market-access event, not a P&L driver. No management press release accompanying these results was available to cross-check against the numbers.